{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:19:02Z","timestamp":1772759942441,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">MORE<\/jats:styled-content> was a four\u2010yr, prospective, observational study at 40 transplant centers in the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>. Data were analyzed to evaluate changes in mycophenolic acid (<jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content>) dosing over time in 904 <jats:italic>de novo<\/jats:italic> kidney transplant recipients receiving enteric\u2010coated mycophenolate sodium (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content>, n\u00a0=\u00a0616) or mycophenolate mofetil (<jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>, n\u00a0=\u00a0288) with tacrolimus. Induction therapy and steroid treatment were similar in the two subpopulations. The proportion of patients receiving the maximal recommended <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> dose was 80.5%, 43.9%, 39.2%, 34.6%, and 30.1% at baseline and years 1, 2, 3, and 4, respectively. More patients received the maximal recommended <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> dose with <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content> at month 1 (79.2% vs. 71.7%, p\u00a0=\u00a00.016), month 3 (68.5% vs. 56.9%, p\u00a0=\u00a00.001), and month 6 (52.9% vs. 44.0%, p\u00a0=\u00a00.028). Multivariate analysis showed the risk of biopsy\u2010proven acute rejection, graft loss or death to be similar for <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>. Estimated glomerular filtration rate (<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>) was similar with <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content> at all time points. There were no significant differences in any category of adverse event between the <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content> cohorts during follow\u2010up, including gastrointestinal events. In conclusion, <jats:styled-content style=\"fixed-case\">MPA<\/jats:styled-content> dose was maintained more effectively in the first six\u00a0months after kidney transplantation using <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">MPS<\/jats:styled-content> vs. <jats:styled-content style=\"fixed-case\">MMF<\/jats:styled-content>, without an increase in adverse events.<\/jats:p>","DOI":"10.1111\/ctr.12392","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T08:10:34Z","timestamp":1401869434000},"page":"961-967","source":"Crossref","is-referenced-by-count":7,"title":["Long\u2010term dosing patterns of enteric\u2010coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation"],"prefix":"10.1111","volume":"28","author":[{"given":"Anthony","family":"Langone","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad","family":"Shihab","sequence":"additional","affiliation":[{"name":"School of Medicine University of Utah Salt Lake City UT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleh","family":"Pankewycz","sequence":"additional","affiliation":[{"name":"Erie County Medical Center Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cataldo","family":"Doria","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Wiland","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McCague","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Chan","sequence":"additional","affiliation":[{"name":"School of Medicine University of Colorado Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Summary of Product Characteristics","author":"Cellcept\u00ae","year":"2012"},{"key":"e_1_2_7_3_1","volume-title":"Summary of Product Characteristics","author":"Myfortic\u00ae","year":"2012"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000079616.71891.F5"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318186dc81"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826110-00007"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000225760.09969.1f"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01966.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.06.053"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00877.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31822527ca"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2004.00318.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00337.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.513379"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0b013e318205568c","article-title":"Enteric\u2010coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double\u2010blind, randomized study","volume":"91","author":"Langone AJ","year":"2011","journal-title":"Transplantation"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000290678.06523.95"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000209411.66790.b3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.01.184"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.07.041"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2005.00134.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.11.013"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.183"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31817fdddb"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.09.014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12035"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12392","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:21:14Z","timestamp":1695572474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ctr.12392"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12392","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}